SQUAMOUS CELL CARCINOMA
-
Merck scraps two late-stage trials of cancer drug Keytruda
Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial failures for the blockbuster drug.
-
Study suggests that simple laser treatments may help prevent nonmelanoma skin cancer
-
Scientists gain insight into the molecular mechanisms of squamous cell cancer
-
Quick and Dirty DNA Repair sets the stage for smoking related lung cancer
-
The head and neck cancer market will grow strikingly from $386 million in 2014 to $1.53 billion by 2024
Advertisement
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
